David Kavanagh News Today

Approximately one to two people per million worldwide are diagnosed with C3G every year

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Everyone in Hollywood is using AI, but they are scared to admit it, experts say about artificial intelligence.

The issue of AI looks to only get more and more complicated with every new ability and every new improved version. However, could it serve as a language-bridging tool?

Tipp dealer sells Ireland’s first two biogas tractors 2023-10-25

The High Kings play the FLATO Academy Theatre Sept. 23 as part of their first tour of Canada.

A pioneering drug for a rare kidney disease prevents organ failure and significantly improves the outcome for patients, new research has confirmed.